Medical treatment of rare diseases must be put on the agenda

Medical treatment of rare diseases must be put on the agenda Editorial (2490) Total Article Views Authors: Aagaard L Published Date September 2011 Volume 2011:1 Pages 1 - 2 DOI: http://dx.doi.org/10.2147/ODRR.S25714 Lise Aagaard Faculty of Pharmaceutical Sciences, University of Copenhagen, University of Copenhagen, Copenhagen, Denmark The development of medicines for the treatment of rare diseases is important to many, including both patients and prescribers, but has traditionally been of minor interest to the pharmaceutical industry due to the often low number of patients with a rare disease. Politicians and regulators have recently acknowledged this problem, and favorable licensing conditions are now offered to pharmaceutical companies developing new medications for rare diseases to make these products more accessible. Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Professor Lise Aagaard The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies Readers of this article also read: Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite Wine consumers’ environmental knowledge and attitudes: Influence on willingness to purchase Imaging of peripheral vascular disease Exacerbation rate, health status and mortality in COPD – a review of potential interventions The pathophysiology of bronchiectasis Food nanotechnology – an overview Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome Lyme disease: the next decade Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation Topical azithromycin or ofloxacin for endophthalmitis